What is the Fiscal Year for Cingulate Therapeutics?
Date: November 13, 2026
Cingulate Therapeutics's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q2, which ends on June 30, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q2
Current Quarter End
June 30, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Kansas City, Kansas, United States
Industry
Manufacturing, Pharmaceuticals Manufacturing
Stock Symbol
CING
Website
https://cingulate.comDescription
Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Cingulate Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.